A Blind, Randomized and Controlled Clinical Trial to Evaluate the Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccines for Healthy Children
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Varicella
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
- Enrollment
- 5997
- Locations
- 2
- Primary Endpoint
- The protection rate of the vaccine
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine in healthy children.
Detailed Description
This study is a randomized, blind, controlled phase III clinical trial. The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control is diluent of lyophilized vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. All participants are healthy, and will be randomly assigned into experimental group or control group in the ratio 1:1.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy volunteer between 1 - 12 years old;
- •Proven legal identity;
- •Guardian(s) of the volunteer and/or volunteers themselves should be capable of understanding the written consent form, and such form should be signed before the volunteer being included into this study;
Exclusion Criteria
- •Prior vaccination with varicella vaccine or with history of varicella zoster virus (VZV) infection;
- •Axillaty temperature \> 37.0 °C;
- •History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;
- •History of epilepsy, seizures or convulsions, or a family history of mental illness, autoimmune disease or immunodeficiency;
- •Severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases;
- •Acute disease or acute stage of chronic disease within 7 days prior to study entry;
- •Receipt of any of the following products:
- •Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
- •Any live attenuated vaccine within 1 month prior to study entry;
- •Any blood product, immunosuppressant, hormone, or other investigational medicine(s) within 30 days prior to study entry;
Outcomes
Primary Outcomes
The protection rate of the vaccine
Time Frame: ≥30 cases reported after 30 days of the injection
The protection rate will be calculated based on the reported cases occurred 30 days after injection.
The incidences of varicella of each group
Time Frame: ≥30 cases reported 30 days after injection
The first 30 cases of varicella occurred 30 days after injection will be collected.
Secondary Outcomes
- The incidences of serious adverse events (SAEs) of each group(6 months)
- The seroconversion rate of the immunogenicity group(30 days after injection)
- The incidences of adverse events (AEs) of each group(30 days)
- The geometric mean titer (GMT) of the immunogenicity group(30 days)
- The geometric mean fold increase (GMI) of the immunogenicity group(30 days after injection)